Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 4:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: HIV Infected Individuals Clear all
Completed No phase listed Observational Accepts healthy volunteers

F 18 T807 PET (Positron Emission Tomograph )Scan for HIV Infected & Uninfected

NCT03279523
View directory record Official record
Conditions
Alzheimer Disease, HIV
Interventions
F 18 T807
Drug
Lead sponsor
Tammie L. S. Benzinger, MD, PhD
Other
Eligibility
40 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 21, 2020 · Synced Sep 27, 2026, 4:36 PM EDT
Completed Phase 1 Interventional

Safety of and Immune System Response to an HIV Vaccine (EP HIV-1090) in HIV Infected Patients

NCT00052182
View directory record Official record
Conditions
HIV Infections
Interventions
EP HIV-1090
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 59 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 22, 2007 · Synced Sep 27, 2026, 4:36 PM EDT
Completed Phase 3 Interventional

The Safety and Effectiveness of Adefovir Dipivoxil in the Treatment of HIV-Infected Patients

NCT00001082
View directory record Official record
Conditions
Cytomegalovirus Infections, HIV Infections
Interventions
Levocarnitine, Adefovir dipivoxil, Adefovir dipivoxil placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
505 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 1999
U.S. locations
15
States / cities
San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2013 · Synced Sep 27, 2026, 4:36 PM EDT
Terminated Not applicable Interventional Results available

Raltegravir Cerebrospinal Fluid Pharmacodynamic Study in HIV-Infected Individuals

NCT01293123
View directory record Official record
Conditions
HIV
Interventions
Raltegravir, Efavirenz
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 30, 2019 · Synced Sep 27, 2026, 4:36 PM EDT
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Effect of Rosuvastatin on Endothelial Function

NCT00986999
View directory record Official record
Conditions
HIV Infections, Cardiovascular Disease
Interventions
rosuvastatin
Drug
Lead sponsor
University of Hawaii
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Jan 28, 2015 · Synced Sep 27, 2026, 4:36 PM EDT
Terminated Phase 4 Interventional Results available

Raltegravir vs. Lopinavir/Ritonavir, Both in Combination With Truvada, in HIV+ Treatment Naive Individuals

NCT00632970
View directory record Official record
Conditions
HIV Infections
Interventions
Raltegravir, Lopinavir/Ritonavir, Truvada
Drug
Lead sponsor
George Washington University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Sep 27, 2026, 4:36 PM EDT
Completed Phase 3 Interventional

A Double-Blind, Randomized, Dose Response Study of Three Doses of Delavirdine Mesylate (U-90152S) in Combination With Zidovudine (ZDV) Versus ZDV Alone in HIV-1 Infected Individuals With CD4 Counts of 200-500mm3

NCT00002124
View directory record Official record
Conditions
HIV Infections
Interventions
Delavirdine mesylate, Lamivudine, Zidovudine
Drug
Lead sponsor
Pharmacia and Upjohn
Industry
Eligibility
14 Years and older
Enrollment
1,250 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
87
States / cities
Birmingham, Alabama • Berkeley, California • Clovis, California + 63 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 27, 2026, 4:36 PM EDT
Completed Phase 4 Interventional

A Pharmacokinetic (PK) Study of a Combination of Indinavir, Ritonavir, and Amprenavir

NCT00148785
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir/Ritonavir/Fosamprenavir
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 10, 2013 · Synced Sep 27, 2026, 4:36 PM EDT
Terminated Phase 1 Interventional Results available

Combination Therapy With 3BNC117 and 10-1074 in HIV-Infected Individuals

NCT03571204
View directory record Official record
Conditions
HIV
Interventions
3BNC117 and 10-1074, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 8, 2022 · Synced Sep 27, 2026, 4:36 PM EDT
Completed Phase 1 Interventional

A Phase I Study to Evaluate the Immunologic Response and Virologic Impact of AGS-004

NCT02042248
View directory record Official record
Conditions
HIV
Interventions
AGS-004
Biological
Lead sponsor
Cynthia L Gay, MD
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 3, 2017 · Synced Sep 27, 2026, 4:36 PM EDT
Withdrawn Not applicable Interventional

Effect of a Change in HIV Therapy on Liver Steatosis, Inflammation, and Fibrosis

NCT00023218
View directory record Official record
Conditions
HIV Infections, Hepatitis C
Interventions
Lopinavir/Ritonavir, Efavirenz
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
Honolulu, Hawaii • Tripler AMC, Hawaii • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 8, 2015 · Synced Sep 27, 2026, 4:36 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Safety and Antiretroviral Activity of 3BNC117

NCT02588586
View directory record Official record
Conditions
HIV-1 Infection
Interventions
3BNC117, Antiretroviral Treatment Interruption
Drug · Other
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 15, 2021 · Synced Sep 27, 2026, 4:36 PM EDT
Terminated Not applicable Interventional

Digital Behavioral Therapy for Sleep Problems

NCT04308499
View directory record Official record
Conditions
Insomnia
Interventions
Digital cognitive-behavioral therapy for insomnia (dCBTI), Sleep hygiene education (SHE)
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Sep 27, 2026, 4:36 PM EDT
Completed Not applicable Interventional

Safety and Effectiveness of Giving Combinations of Three or Four Anti-HIV Drugs to HIV-Infected Patients

NCT00002211
View directory record Official record
Conditions
HIV Infections
Interventions
Nelfinavir mesylate, Delavirdine mesylate, Stavudine, Didanosine
Drug
Lead sponsor
Pharmacia and Upjohn
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Peapack, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 27, 2026, 4:36 PM EDT
Completed No phase listed Observational

Neurocognitive Effects and Tolerability of Efavirenz in Aging HIV-infected Individuals ("SHAC Neuro Study")

NCT01985399
View directory record Official record
Conditions
HIV, AIDS
Interventions
Neuropsychological testing
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
50 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Oct 16, 2016 · Synced Sep 27, 2026, 4:36 PM EDT
Completed Phase 4 Interventional Results available

Improving Immunogenicity of Influenza Vaccine in HIV Infected Individuals

NCT01262846
View directory record Official record
Conditions
HIV Infection
Interventions
Fluzone®
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Sep 27, 2026, 4:36 PM EDT
Completed Not applicable Interventional

Zinc Therapy in HIV Infected Individuals Who Abuse Drugs

NCT00149552
View directory record Official record
Conditions
HIV Infections, Substance-Related Disorders
Interventions
zinc
Dietary Supplement
Lead sponsor
Florida International University
Other
Eligibility
18 Years and older
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 4, 2012 · Synced Sep 27, 2026, 4:36 PM EDT
Completed Phase 1 Interventional

A Study of Dextran Sulfate in HIV-Infected Patients and in Patients With AIDS or AIDS Related Complex (ARC)

NCT00001009
View directory record Official record
Conditions
HIV Infections
Interventions
Dextran sulfate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1990
U.S. locations
8
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 27, 2026, 4:36 PM EDT
Not listed Phase 2 Interventional

Safety and Effectiveness of Giving CPI-1189 to HIV-Infected Patients With AIDS Dementia

NCT00002414
View directory record Official record
Conditions
HIV Infections
Interventions
CPI-1189
Drug
Lead sponsor
Centaur Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
6
States / cities
San Diego, California • Chicago, Illinois • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 27, 2026, 4:36 PM EDT
Completed Phase 1 Interventional

PENNVAX-B With or Without IL-12 or IL-15 as a DNA Vaccine for HIV Infection

NCT00775424
View directory record Official record
Conditions
HIV Infection
Interventions
PENNVAX-B, GENEVAX IL-12-4532, PLACEBO, IL-15 adjuvant
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 50 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 24, 2016 · Synced Sep 27, 2026, 4:36 PM EDT
Completed Phase 1 Interventional

3BNC117 and 10-1074 in HIV-infected Individuals

NCT02825797
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV)
Interventions
3BNC117, 10-1074, Analytical treatment interruption, Placebo
Drug · Other
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 20, 2018 · Synced Sep 27, 2026, 4:36 PM EDT
Completed Phase 1 Interventional

Determining Responses to Two Different Vaccines in HIV and HCV Infected Individuals

NCT00393276
View directory record Official record
Conditions
HIV Infections, Hepatitis C
Interventions
Twinrix, Decavac
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
11
States / cities
San Diego, California • San Francisco, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 27, 2026, 4:36 PM EDT
Completed Phase 1Phase 2 Interventional

Safety of and Immune Response to a DNA HIV Vaccine (VRC-HIVDNA009-00-VP) in HIV Infected Individuals With Acute HIV Infection

NCT00125099
View directory record Official record
Conditions
HIV Infections
Interventions
VRC-HIVDNA009-00-VP
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2007
U.S. locations
5
States / cities
San Diego, California • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 27, 2026, 4:36 PM EDT
Completed Phase 1Phase 2 Interventional Results available

High-Dose Fluconazole for the Treatment of Cryptococcal Meningitis in HIV-Infected Individuals

NCT00885703
View directory record Official record
Conditions
Cryptococcal Meningitis, HIV Infections
Interventions
Fluconazole, Amphotericin B
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 27, 2026, 4:36 PM EDT